India, Nov. 17 -- image credit- shutterstock

Pfizer has announced the launch of a Rimegepant ODT in India for acute treatment of migraine, with or without aura, in adults with a previous insufficient response to triptan. The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches.

It also enables early return to function and sustained relief from most bothersome symptoms. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water.

Rimegepant sets a new standard in comprehensive migraine care in the Indian market by providing timely and quick pai...